Dr. Lesokhin on the Current Treatment Landscape of Myeloma

Video

In Partnership With:

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.

The treatment paradigm has evolved continuously over the last 4 to 5 years, due in large part to the ongoing development of monoclonal antibodies, second-generation proteasome inhibitors, and the combination of immunomodulatory drugs (IMiDs) and monoclonal antibodies. Specifically, in the first-line setting, it is now the standard of care to administer 3-drug regimens of a proteasome inhibitor, IMiD, and dexamethasone, explains Lesokhin. A patient will then receive a stem cell transplant if they are eligible, followed by maintenance therapy. Transplant ineligible patients will receive induction therapy followed by maintenance therapy of lenalidomide (Revlimid).

In the relapsed setting, there a number of available 3-drug regimens, Lesokhin says. Lenalidomide, dexamethasome, and carfilzomib (Kyprolis), daratumumab (Darzalex), dexamethasone, and lenalidomide, as well as daratumumab, pomalidomide (Pomalyst) and dexamethasone have all been effective in this space, says Lesokhin.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD